加载中
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
前收盘价
US$3.15
+US$0.01 · +0.32%
盘中时间采用ET。市场数据可能有所延迟。
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
日内区间
当前US$3.15
52周区间
当前US$3.15
盘中时间采用ET。市场数据可能有所延迟。
Based in Shanghai, People's Republic of China, 111, Inc. (established in 2010 and formerly known as New Peak Group until April 2018) is a prominent entity in the Chinese healthcare sector, operating a comprehensive online-to-offline (O2O) ecosystem. Its operations are structured across both business-to-business (B2B) and business-to-consumer (B2C) channels. The company facilitates the sale of a wide array of medical and wellness products, reaching customers through its online retail channels as well as wholesale and retail pharmacy networks. This extensive product catalog encompasses prescription medications, over-the-counter drugs (both Western and traditional Chinese), dietary supplements like vitamins, optical products such as contact lenses, various medical supplies and devices (e.g., bandages, thermometers), personal care items (including skincare, birth control, and sexual wellness products), and infant care essentials. Beyond product sales, 111, Inc. provides value-added services to consumers, such as online consultation and electronic prescription fulfillment. For its business partners, the company manages an online marketplace enabling third-party vendors to directly supply pharmacies. It further supports its "1 Pharmacy" clients – comprising pharmacies and wholesalers – with online loan application services, alongside offering data and supply chain integration solutions. Its operational scope also extends to critical back-end functions, including warehousing, logistics management, procurement, research and development, consulting, as well as software development and IT support. As of December 31, 2021, its physical footprint included 14 retail pharmacies operating under the "Yi Hao Pharmacy" brand across several key regions: Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan. The company caters to a diverse clientele, encompassing individual consumers, pharmacies, pharmaceutical manufacturers and distributors, medical practitioners, and insurance providers.
日内区间
当前US$3.15
52周区间
当前US$3.15
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CNY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 122.14亿 CNY | 144.01亿 CNY | 149.48亿 CNY | 135.17亿 CNY | 124.26亿 CNY |
| 销货成本 | 115.1亿 CNY | 135.72亿 CNY | 140.99亿 CNY | 126.77亿 CNY | 118.05亿 CNY |
| 毛利 | 7.04亿 CNY | 8.29亿 CNY | 8.49亿 CNY | 8.4亿 CNY | 6.21亿 CNY |
| 销售、一般及管理费用 | 6.55亿 CNY | 3.85亿 CNY | 6.73亿 CNY | 6.64亿 CNY | 7.2亿 CNY |
| 营业费用 | 7.14亿 CNY | 8.27亿 CNY | 11.99亿 CNY | 12.11亿 CNY | 12.63亿 CNY |
| 利息收入 | 377.92万 CNY | 704.1万 CNY | 883.4万 CNY | 811.8万 CNY | 977.6万 CNY |
| 利息支出 | 3460.28万 CNY | 2833.1万 CNY | 2014.1万 CNY | 1344.3万 CNY | 548.8万 CNY |
| 折旧和摊销 | 1184万 CNY | 1696.7万 CNY | 2178万 CNY | 4081.9万 CNY | 2722.1万 CNY |
| 营业利润 | −1002.81万 CNY | 211.4万 CNY | −3.5亿 CNY | −3.71亿 CNY | −6.42亿 CNY |
| 净利润 | −1684.33万 CNY | −6474.3万 CNY | −3.93亿 CNY | −4.17亿 CNY | −6.7亿 CNY |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
